Gabather
Research Gabather (GABA.ST) on Bullrun: market cap SEK 20.02M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGABA.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 20.02M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 1.07M
- Free cash flow-SEK 331.00K
Valuation Snapshot
latest market cap is SEK 20.02M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 4.56M | -SEK 7.21M | n/a | -0.04 | SEK 3.14M | n/a | SEK 662.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | SEK 20.02M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Gabather
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gabather's market cap?
Gabather's market capitalization is SEK 20.02M.
What does Gabather do?
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.